If you ask me, Positron is in a situation where they will need to be bought out in order to stay 'in business'. Even if not positron anymore, it allows them to keep working. That said, they also have a unique product with a corner on a niche market.
All of this (considering it is true) means that a large biomed corporation would be silly not to pick up POSC and it's technology for what would technically be cheap.
If you have Level 2 sources, watch for the large block buys without sellbacks. Look for the selling volume to get smaller and we will see prices go up.
-PM
Take it at face value, do your due dilligence, the usual stuff...